“Pfizer is dedicated to broadening vaccine access and helping to improve health outcomes around the world, and we’re proud to make Prevenar 13 available through the AMC program,” said Susan Silbermann, president, vaccines at Pfizer. “Strong vaccination programs are a cornerstone of economic development – a simple intervention that has dramatic short and long term impact on health. Since first offering Prevenar 13 through the AMC in 2010, we have continued to support this revolutionary public health program that helps those most in need of potentially lifesaving vaccinations.”
Pfizer entered into the first Supply Agreement to participate in the AMC in March 2010, and then expanded its commitment through a second Supply Agreement in 2011, pledging to supply Prevenar 13 through 2023. Since Pfizer’s original agreement with the AMC in 2010, more than 20 countries have introduced Prevenar 13 into their immunization programs, 3 and pneumococcal vaccines are expected to reach more than 50 GAVI-supported countries by 2015. 3 Prevenar 13 was first introduced for use in infants and young children in December 2009 in Europe and is now approved for such use in more than 120 countries worldwide. Prevenar 13 is also approved for use in children six weeks to 17 years old and adults 18 and older in Europe and certain other countries. In the United States, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]) is not indicated for the prevention of pneumococcal pneumonia in the pediatric population and is not approved for adults 18 through 49 years of age. 5
Prevenar 13 is the most widely used pneumococcal conjugate vaccine in the world, and more than 500 million doses of Prevenar/Prevenar 13 have been distributed worldwide. 4 Prevenar 13 offers the broadest serotype coverage of any currently available pneumococcal conjugate vaccine for prevention of pneumococcal disease. 1,5
About Advance Market Commitments (AMCs)The AMC is a public-private health funding mechanism administered by the GAVI Alliance that is designed to create a sustainable marketplace, ensure an affordable and stable supply of newer vaccines at a steeply discounted price and stimulate the development and expansion of manufacturing capacity for vaccines specifically for the world's poorest countries.